Published in Dig Dis on April 21, 2008
HLA-DQA1 and HLA-DQB1 in Celiac disease predisposition: practical implications of the HLA molecular typing. J Biomed Sci (2012) 1.08
Coeliac disease: changing diagnostic criteria? Gastroenterol Hepatol Bed Bench (2012) 0.93
Wheat-related disorders: A broad spectrum of 'evolving' diseases. United European Gastroenterol J (2014) 0.85
A new algorithm for the diagnosis of celiac disease. Cell Mol Immunol (2011) 0.77
Celiac disease and myointimal proliferation: a possible correlation? Case Rep Gastroenterol (2008) 0.75
Phenotypical characterization of the peripheral blood T cells in patients with celiac disease: does it differentiate suspicious celiac disease cases? Gastroenterol Hepatol Bed Bench (2015) 0.75
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology (2009) 4.16
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol (2010) 3.32
Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. Alcohol Clin Exp Res (2013) 2.84
Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med (2006) 2.55
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2014) 2.47
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology (2006) 2.35
Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol (2014) 2.21
Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol (2009) 2.17
Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol (2009) 2.14
Different Antibiotic No Culture Eradicating (DANCE) strategy: an easy way to manage H. pylori eradication. Dig Liver Dis (2012) 2.11
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol (2002) 2.01
Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol (2005) 1.82
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol (2010) 1.69
Acute cryptogenic liver failure in an untreated coeliac patient: a case report. Eur J Gastroenterol Hepatol (2005) 1.65
Lack of endoscopic visualization of intestinal villi with the "immersion technique" in overt atrophic celiac disease. Gastrointest Endosc (2003) 1.64
Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol (2006) 1.62
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol (2013) 1.62
The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord (2013) 1.62
Obstructive sleep apnea syndrome affects liver histology and inflammatory cell activation in pediatric nonalcoholic fatty liver disease, regardless of obesity/insulin resistance. Am J Respir Crit Care Med (2014) 1.60
Increased serum high-density lipoprotein-cholesterol concentration in celiac disease after gluten-free diet treatment correlates with body fat stores. J Clin Gastroenterol (2009) 1.54
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis (2010) 1.54
Endometriosis, need for a multidisciplinary clinical setting: the internist's point of view. Intern Emerg Med (2010) 1.53
Image-enhanced endoscopy with I-scan technology for the evaluation of duodenal villous patterns. Dig Dis Sci (2012) 1.52
Saccharomyces cerevisiae-associated diarrhea in an immunocompetent patient with ulcerative colitis. J Clin Gastroenterol (2003) 1.48
The European experience with double-balloon enteroscopy: indications, methodology, safety, and clinical impact. Gastrointest Endosc (2005) 1.41
Bacillus subtilis isolated from the human gastrointestinal tract. Res Microbiol (2008) 1.38
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2012) 1.35
Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS (2002) 1.34
Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol (2002) 1.32
Commensal Clostridia: leading players in the maintenance of gut homeostasis. Gut Pathog (2013) 1.19
Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol (2005) 1.18
TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol (2006) 1.17
Granulocyte-colony stimulating factor promotes liver repair and induces oval cell migration and proliferation in rats. Gastroenterology (2007) 1.17
CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis (2008) 1.15
Review article: inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol (2003) 1.15
Extragastric diseases and Helicobacter pylori. Helicobacter (2013) 1.14
Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. Cancer (2014) 1.13
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer (2013) 1.12
Helicobacter pylori and extragastric diseases. Best Pract Res Clin Gastroenterol (2007) 1.12
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving. Addict Biol (2011) 1.11
Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation (2002) 1.11
Extragastric manifestations of Helicobacter pylori infection. Helicobacter (2010) 1.11
Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget (2011) 1.11
Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol (2010) 1.11
Relationship between ghrelin levels, alcohol craving, and nutritional status in current alcoholic patients. Alcohol Clin Exp Res (2006) 1.09
Faecal calprotectin concentrations in untreated coeliac patients. Scand J Gastroenterol (2007) 1.09
The mitochondrial permeability transition pore and cyclophilin D in cardioprotection. Biochim Biophys Acta (2011) 1.07
Sequential or combined treatment? That is the question. Radiology (2014) 1.07
Sonography and clinical outcome of viable hydatid liver cysts treated with double percutaneous aspiration and ethanol injection as first-line therapy: efficacy and long-term follow-up. AJR Am J Roentgenol (2009) 1.05
Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol (2008) 1.05
Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol (2009) 1.05
Regional cerebral hypoperfusion in patients with celiac disease. Am J Med (2004) 1.03
Extragastric manifestations of Helicobacter pylori infection. Helicobacter (2011) 1.02
Third-line rescue therapy for Helicobacter pylori infection. World J Gastroenterol (2006) 1.02
Therapeutic implications of mesenchymal stem cells in liver injury. J Biomed Biotechnol (2011) 1.02
Isolation and characterization of hepatic stem cells, or "oval cells," from rat livers. Methods Mol Biol (2009) 1.02
The role of IL-15 in gastrointestinal diseases: a bridge between innate and adaptive immune response. Cytokine Growth Factor Rev (2013) 1.01
Association between hypothyroidism and small intestinal bacterial overgrowth. J Clin Endocrinol Metab (2007) 1.01
Autoimmune enteropathy in children and adults. Scand J Gastroenterol (2009) 1.00
Gut microbiota and obesity. Intern Emerg Med (2010) 1.00
Helicobacter pylori, gastrointestinal symptoms, and metabolic control in young type 1 diabetes mellitus patients. Pediatrics (2003) 1.00
Increased frequency of Ig heavy-chain HS1,2-A enhancer *2 allele in dermatitis herpetiformis, plaque psoriasis, and psoriatic arthritis. J Invest Dermatol (2008) 0.99
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology (2013) 0.99
Extragastric manifestations of Helicobacter pylori infection. Helicobacter (2012) 0.99
Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol (2002) 0.99
The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol (2012) 0.98
Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med (2002) 0.98
The role of methane in intestinal diseases. Am J Gastroenterol (2010) 0.98
Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells. Digestion (2004) 0.98
Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. Eur J Endocrinol (2014) 0.97
Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. Am J Gastroenterol (2009) 0.97
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. Am J Gastroenterol (2003) 0.97
Rapid regression of psoriasis in a coeliac patient after gluten-free diet. A case report and review of the literature. Digestion (2003) 0.97
Coronary atherosclerotic burden in patients with infection by CagA-positive strains of Helicobacter pylori. Coron Artery Dis (2010) 0.96
Management and treatment of lactose malabsorption. World J Gastroenterol (2006) 0.96
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells. Cancer Metab (2013) 0.96
Clinical use of albumin in hepatology. Blood Transfus (2009) 0.96
Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. Biomed Res Int (2013) 0.95
Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target. Curr Pharm Des (2013) 0.95
Helicobacters and extragastric diseases. Helicobacter (2009) 0.95
Extragastric manifestations of Helicobacter pylori infection -- other Helicobacters. Helicobacter (2007) 0.95